
Cardiology fellow @virtuaCVfellows | #ACCFIT | @teachforamerica | @umassamherst ‘15 | @RowanVirtuaSOM ‘21
Joined August 2009
- Tweets9.3K
- Following1.6K
- Followers664
- Likes20.7K
Trinava Roy, DO retweeted
First case in Northeast with Tactiflex DUO and what a great case it turned out - epicardial LV summit pvc mapped earliest with EP star epicardially , successfully ablated endocardial with stacked PFA despite being barely on time endocardial.
@EPeeps_Bot @AbbottCardio
Trinava Roy, DO retweeted
Refs ALREADY doing everything they can to help the Spurs. This was called an OFFENSIVE foul on KAT 😂🤣
Trinava Roy, DO retweeted
Our goalie decided we weren’t gonna lose today.. One of the greatest American sport performances of all time
🗣🗣 THANK YOU FOR STANDING ON YOUR HEAD CONNOR HELLEBUYCK
🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸
Trinava Roy, DO retweeted
Dr. Harb presenting a very interesting case of Simultaneous Massive PE and RCA STEMI in the Setting of Provoked Venous Thromboembolism and Patent Foramen Ovale! 👏👏
#AHA2025 @CircAHA @VirtuaCVFellows @Troy06 @BeshaiRafail @VirtuaHealth
ahajournals.org/doi/10.1161/…
Trinava Roy, DO retweeted
Replying to @Troy06 @SuzanneJBaron @purviparwani @JamalRanaMD @DrMarthaGulati @AnkurKalraMD @SVRaoMD @baileyannRN @djc795 @dranulala @JasonKatzMD
So happy to hear that! I kept my hobbies up in fellowship and I encourage all my fellows to do the same. Learn and do the hard work but then keep being you. @TanyaSh112 @ABaliMD @ameeshisath @SwatiChand_ @jay_sreenivasan
Trinava Roy, DO retweeted
Replying to @KinturSanghvi
@KinturSanghvi dropping knowledge on AC/AP in the cath lab during cath conference! Thank you for keeping us on our toes!
@BeshaiRafail @patel_anjeli @Mazi_Daneshvar @Troy06
Trinava Roy, DO retweeted
What is the optimal systolic BP control target in type 2 diabetes patients? #AHA24
Blood Pressure Control Target in Diabetes (BROAD) Study shows intensive SBP lowering (<120 mmHg)
⬇️ MACE by 21% c/w standard treatment (<140 mmHg) bit.ly/3AxkFHe
Trinava Roy, DO retweeted
Unfortunately not able to attend #AHA2024 in person this year but check out these presentations my co-residents @christianacare and I put together for @AHAScience!!
Trinava Roy, DO retweeted
Important topic @EkateriniL @ErinMichos @IzaUchmanowicz @JamalRanaMD @HeartOTXHeartMD @scottisaacsmd @FaustoHerediaDr @VietHeartPA et al
📚 Intensity or volume: the role of physical activity in longevity
✏️ 7158 participants
✏️ Intensity is a main driver of ⬇️ mortality risk suggesting the intensity of physical activity rather than the quantity matters for longevity bit.ly/3U9z7vp
@EJPCEiC @SilCastelletti @peronefrancesco @savvashad @EAPCPresident @andreagallardo #cvprev #CVD #EAPC_ESC #EJPC
Trinava Roy, DO retweeted
GM! Presented by @akshaydesaimd just a few moments ago.
FINEARTS-HF: HFmrEF/ HFpEF patients
Recent WHF with greater absolute risk reduction with Finerenone in total WHF events & CV death
@HFSA #HFSA2024
Trinava Roy, DO retweeted
I'm fully down the rabbit hole tonight - thinking about ventricular-arterial interactions in HF (HFrEF vs HFpEF). A quick thread (based off this 2012 JACC paper from Barry Borlaug and colleagues @MayoClinicCV)...
sciencedirect.com/science/ar…
Trinava Roy, DO retweeted
HFstats.org from @hfsa is now LIVE!
Graphics, slides, fact sheets, etc!!
You can check out the full stats doc @JCardFail
onlinejcf.com/article/S1071-…
@dranulala @gcfmd @hmkyale @mvaduganathan @BiykemB @DukeHFDoc
HFStats.org is here! When you need key #heartfailure statistics for presentations, research, or social media discussions, turn to HF Stats. The graphics, slides, fact sheets, and infographics feature data derived from the annual HF Stats report in @JCardFail. They’re easy to download and share. See for yourself at hfstats.org
Trinava Roy, DO retweeted
Peep the name change and new profile pic! Beyond excited that ERAS 2025 Fellowship season has begun! Looking forward to applying to cardiology this season and eager to meet you all along the interview trail! Can’t wait to discuss my passions of critical care and heart failure!
Trinava Roy, DO retweeted
🚨#FLOW: The most anticipated trial of the year now published in @NEJM with #ERA24
Semaglutide 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD, cementing itself as a new pillar of care.
🧵 on key thoughts 👇🏾
nejm.org/doi/full/10.1056/NE…















































